Profile: Osiris Therapeutics Inc (OSIR.OQ)
6 Dec 2013
Osiris Therapeutics, Inc. (Osiris), incorporated in April 2002, is a stem cell therapeutic company. The Company focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The Company operates in two business segments: Therapeutics and Biosurgery. The Company's Therapeutics business is focused on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Company's Biosurgery business, works to harness the ability of cells and novel constructs to promote the body's natural healing. In the Company's Biosurgery business, the Company manufactures , market and distributes Grafix and Ovation for tissue repair. In the Company's Therapeutics segment, its pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee.
The Company's Therapeutics segment is focused on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Company's biologic drug candidate, Prochymal (remestemcel-L), is being evaluated in clinical trials for a number of indications, including acute graft versus host disease (GvHD), Crohn's disease, acute myocardial infarction, type 1 diabetes and gastrointestinal injury resulting from radiation exposure (animal rule). Prochymal is the stem cell therapeutic which is granted both Orphan Drug and Fast Track status by the United States Food and Drug Administration (FDA). Its pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for osteoarthritis in the knee.
The Company also partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In addition, it also partnered with the Juvenile Diabetes Research Foundation (JDRF) for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. The Company's two biologic drug candidates, Prochymal and Chondrogen, utilize human mesenchymal stem cells (MSCs).
The Company's Biosurgery segment seeks to harness the ability of cells and novel constructs to promote the body's natural healing. The Company launched limited commercial distribution of several products developed and manufactured by its Biosurgery segment, including Grafix and Ovation.
Its Grafix is a three-dimensional tissue matrix designed for application directly to acute and chronic wounds, including diabetic foot ulcers and burns. This cellular repair matrix provides a rich source of extracellular matrix, viable endogenous MSCs and epithelial cells, as well as growth factors directly to the site of the wound, protecting the area from inflammation, scarring and infection. Ovation is a novel cellular repair matrix designed for use in surgical applications where bone tissue repair is needed. Ovation provides the three essential components of periosteum, collagen matrix, viable endogenous MSCs.
Osiris Therapeutics Inc
7015 Albert Einstein Drive
COLUMBIA MD 21046